Author Index Volume 1 (2015)

Al-Ahmadie, H.A., see Garcia-Cao, M. (2) 159–170

Bangs, R., see Quale, D.Z. (2) 117–122

Barqawi, Z., see Krughoff, K. (2) 171–179

Benezra, R., see Garcia-Cao, M. (2) 159–170

Benson, C.R., see Rozanski, A.T. (1) 91–96

Berry, D.L., M. Nayak, B. Halpenny, S. Harrington, K.R. Loughlin, P. Chang, J.E. Rosenberg and A.S. Kibel, Treatment Decision Making in Patients with Bladder Cancer (2) 151–158

Bivalacqua, T.J., see Lerner, S.P. (1) 29–30

Bochner, B.H., see Garcia-Cao, M. (2) 159–170

Booth, C.M., see Robinson, A.G. (2) 123–131

Buchwald, Z.S. and J.A. Efstathiou, Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer? (1) 15–27

Buck, D., see Jevons, S.J. (1) 31–44

Chang, P., see Berry, D.L. (2) 151–158

Chin, Y., see Garcia-Cao, M. (2) 159–170

Clark, P.E., see Patel, S. (2) 143–150

Dancik, G.M. and D. Theodorescu, The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer (1) 45–63

Demkiw, S., see Quale, D.Z. (2) 117–122

Dinh, T., see Patel, S. (2) 143–150

Dinney, C., see Lerner, S.P. (1) 29–30

Efstathiou, J.A., see Buchwald, Z.S. (1) 15–27

Fiorini, E., see Quale, D.Z. (2) 117–122

Flack, C.K., M.F. Monn, H.Z. Kaimakliotis and M.O. Koch, Functional and Clinicopathologic Outcomes Using a Modified Vescica Ileale Padovana Technique (1) 73–79

Garcia-Cao, M., H.A. Al-Ahmadie, Y. Chin, B.H. Bochner and R. Benezra, Id Proteins Contribute to Tumor Development and Metastatic Colonization in a Model of Bladder Carcinogenesis (2) 159–170

Green, A., see Jevons, S.J. (1) 31–44

Green, C., see Rozanski, A.T. (1) 91–96

Griffin, J., see Hamilton, Z. (2) 137–142

Grossman, H.B., see Rozanski, A.T. (1) 91–96

Guttman, D., see Quale, D.Z. (2) 117–122

Halpenny, B., see Berry, D.L. (2) 151–158

Hamilton, Z., W. Parker, J. Griffin, T. Isaacson, M. Mirza, H. Wyre, J. Holzbeierlein and E.K. Lee, Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy (2) 137–142

Harrington, S., see Berry, D.L. (2) 151–158

Hendricksen, K., see Niegisch, G. (1) 97–103

Holzbeierlein, J., see Hamilton, Z. (2) 137–142

Hulsbergen - van de Kaa, C., see Niegisch, G. (1) 97–103

Ibrahim, A., see Jarow, J. (2) 133–136

Isaacson, T., see Hamilton, Z. (2) 137–142

Izard, J.P., see Robinson, A.G. (2) 123–131

Jarow, J., V.E. Maher, S. Tang, A. Ibrahim, G. Kim, R. Sridhara and R. Pazdur, Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer (2) 133–136

Jevons, S.J., A. Green, G. Lunter, C. Kartsonaki, D. Buck, P. Piazza and A.E. Kiltie, High-throughput DNA Sequencing Identifies Novel CtIP (RBBP8) Variants in Muscle-invasive Bladder Cancer Patients (1) 31–44

Joo, K.J., H. Li, X. Zhang and S.P. Lerner, Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex Virus (1) 81–90

Kaimakliotis, H.Z., see Flack, C.K. (1) 73–79

Kamat, A., see Krughoff, K. (2) 171–179

Kamat, A., see Lerner, S.P. (1) 29–30

Kamat, A.M., see Patel, S. (2) 143–150

Kartsonaki, C., see Jevons, S.J. (1) 31–44

Kibel, A.S., see Berry, D.L. (2) 151–158

Kiltie, A.E., see Jevons, S.J. (1) 31–44

Kim, G., see Jarow, J. (2) 133–136

Koch, M.O., see Flack, C.K. (1) 73–79

Krughoff, K., T.P. Lhungay, Z. Barqawi, C. O’Donnell, A. Kamat and S. Wilson, The Prognostic Value of Previous Irradiation on Survival of Bladder Cancer Patients (2) 171–179Lee, C.T., see Patel, S. (2) 143–150

Lee, E.K., see Hamilton, Z. (2) 137–142

Lerner, S.P., C. Dinney, A. Kamat, T.J. Bivalacqua, M. Nielson, M. O’Donnell, M.P. Schoenberg and G. Steinberg, Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG (1) 29–30

Lerner, S.P., see Joo, K.J. (1) 81–90

Lhungay, T.P., see Krughoff, K. (2) 171–179

Li, H., see Joo, K.J. (1) 81–90

Loughlin, K.R., see Berry, D.L. (2) 151–158

Lunter, G., see Jevons, S.J. (1) 31–44

Maher, V.E., see Jarow, J. (2) 133–136

Mayo, K., see Patel, S. (2) 143–150

McCoy, J.A., see Rozanski, A.T. (1) 91–96

Mirza, M., see Hamilton, Z. (2) 137–142

Monn, M.F., see Flack, C.K. (1) 73–79

Nayak, M., see Berry, D.L. (2) 151–158

Necchi, A., see Quale, D.Z. (2) 117–122

Nepple, K.G., see Steinberg, R.L. (1) 65–72

Niegisch, G., C. Hulsbergen - van de Kaa, M. Ploeg, K. Hendricksen and J.A. Witjes, Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue? (1) 97–103

Nielsen, M., see Lerner, S.P. (1) 29-30

Noah-Vanhoucke, J., see Patel, S. (2) 143–150

Northam, T., see Quale, D.Z. (2) 117–122

O’Donnell, C., see Krughoff, K. (2) 171–179

O’Donnell, M., see Lerner, S.P. (1) 29–30

O’Donnell, M.A., see Steinberg, R.L. (1) 65–72

O’Donnell, M.A., see Steinberg, R.L. (2) 105–116

Parker, W., see Hamilton, Z. (2) 137–142

Patel, S., T. Dinh, J. Noah-Vanhoucke, B. Rengarajan, K. Mayo, P.E. Clark, A.M. Kamat, C.T. Lee, W.J. Sexton and G.D. Steinberg, Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients (2) 143–150

Pazdur, R., see Jarow, J. (2) 133–136

Piazza, P., see Jevons, S.J. (1) 31–44

Ploeg, M., see Niegisch, G. (1) 97–103

Quale, D.Z., R. Bangs, M. Smith, D. Guttman, T. Northam, A. Winterbottom, A. Necchi, E. Fiorini and S. Demkiw, Bladder Cancer Patient Advocacy: A Global Perspective (2) 117–122

Raghavan, D., Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years (1) 3–13

Rengarajan, B., see Patel, S. (2) 143–150

Robinson, A.G., J.P. Izard and C.M. Booth, The Role of Population-Based Observational Research in Bladder Cancer (2) 123–131

Rosenberg, J.E., see Berry, D.L. (2) 151–158

Rozanski, A.T., C.R. Benson, J.A. McCoy, C. Green, H.B. Grossman, R.S. Svatek and J.B. Shah, Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging? (1) 91–96

Schoenberg, M.P., see Lerner, S.P. (1) 29–30

Sexton, W.J., see Patel, S. (2) 143–150

Shah, J.B., see Rozanski, A.T. (1) 91–96

Smith, M., see Quale, D.Z. (2) 117–122

Sridhara, R., see Jarow, J. (2) 133–136

Steinberg, G., see Lerner, S.P. (1) 29–30

Steinberg, G.D., see Patel, S. (2) 143–150

Steinberg, R.L., L.J. Thomas and M.A. O’Donnell, Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease (2) 105–116

Steinberg, R.L., L.J. Thomas, M.A. O’Donnell and K.G. Nepple, Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer (1) 65–72

Svatek, R.S., see Rozanski, A.T. (1) 91–96Tang, S., see Jarow, J. (2) 133–136

Theodorescu, D., see Dancik, G.M. (1) 45–63

Thomas, L.J., see Steinberg, R.L. (1) 65–72

Thomas, L.J., see Steinberg, R.L. (2) 105–116

Wilson, S., see Krughoff, K. (2) 171–179

Winterbottom, A., see Quale, D.Z. (2) 117–122

Witjes, J.A., see Niegisch, G. (1) 97–103

Wyre, H., see Hamilton, Z. (2) 137–142

Zhang, X., see Joo, K.J. (1) 81–90